A. For Equity Issues

Name of the Issuer: Ambey Laboratories Limited

1. Type of issue (IPO/FPO) SME IPO

2. Issue size (Rs. Lakh) Rs. 4,467.60 Lakhs

3. **Grade of issue along with name of the rating agency**Not Applicable as IPO on SME Platform of

NSE

176.45 Times

4. Subscription level (number of times). If the issue was undersubscribed, please clarify

how thefunds were arranged.

5. OIB holding (as a % of total outstanding capital) as disclosed to stock exchange.

(i) allotment in the issue
12.25
(ii) at the end of the 1st Quarter immediately after the listing of the issue
12.51
(iii) at the end of 1st FY
NA
(iv) at the end of 2nd FY
NA
(v) at the end of 3rd FY
NA

6. Financials of the issuer (as per the annual consolidated financial results submitted to stock exchange)

(Rs. in Lakhs)

Param eters	January 31, 2024	FY 23	FY 22	FY 21
Income from operations	10,031.76	10,482.12	8,460.07	8,173.94
Net Profit for the period	607.73	456.93	357.47	1,033.67
Paid-up equity share capital	1868.88	1774.94	1774.94	489.35
Reserves excluding revaluation reserves	512.45	(461.34)	(918.27)	(1275.74)

7. Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently

traded/ delisted/ suspended by any stock exchange, etc.)

(i) at the end of 1st $\hat{F}Y$

Frequently traded (as at 31st March 2025)

(ii) at the end of 2nd FY (iii) at the end of 3rd FY

Not Applicable Not Applicable

8. Change, if any, in directors of issuer from the disclosures in the offer document

(i) at the end of 1st FY Not Applicable

(ii) at the end of 2nd FY

Not Applicable

(iii) at the end of 3rd FY

Not Applicable

9. Status of implementation of project/ commencement of commercial production (as submitted to stock exchange)

(i) as disclosed in the offer documentNot Applicable(ii)Actual implementationNot Applicable

(iii)Reasons for delay in implementation, if any

Not Applicable

10. Status of utilization of issue proceeds (as submitted to stock exchange)

(i) as disclosed in the offer document Rs. 4245.44 Lakh

(ii) Actual utilization Rs. 3887.25 Lakh till 30.09.2024

(iii) Reasons for deviation, if any

Not Available

11. Comments of monitoring agency, if applicable (See Regulation 262 of SEBI (ICDR)

Regulations, 2018)

(i) Comments on use of funds

Not Applicable

(ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in Not Applicable the offerdocument

(iii) Any other reservations expressed by the monitoring agency about the end use of funds

Not Applicable

12. Price- related data

Issue price (Rs): 68 per equity share

Price		At close of 30th	At close of	As at the end of 1st FY after the listing of the issue			As at the end of 2nd FY after the listing of the issue			As at the end of 3rd FY after the listing of the issue		
parameters At close of Ca listing day lis	day from		Closing price	High (during the FY)	Low (during the FY)	Closin gprice	High (during the FY)	` 0	Closing price	` 0	Low (during the FY)	
Market Price	89.25	65.9	52.8	40.2	97.2	37.2	-	-	-	-	-	_

Index (of the Designated Stock Exchange):	24,315.95	24,347	24,981.95	23519.35*	26277.35	21281.45	-	-	-	-	-	-
Sectoral Inde x(NSE SME IPO Index)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

^{*}As on last trading day of the Financial Year i.e. 28-03-2025

13. **Basis for Issue Price and Comparison with Peer Group** (Source of accounting ratios of peer group may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

EPS Pe	eer Group: tul Limited leghmani Organics Limited	2.57 187.05 9.85	NA NA NA	NA NA	NA
At Mo	tul Limited Meghmani Organics Limited				NY 4
Iss	leghmani Organics Limited				N T A
Iss		9.85	NA	N T A	NA
	ssuer			NA	NA
D/D		20.42	NA	NA	NA
P/E	eer Group:				
Atı	tul Limited	46.90	NA	NA	NA
M	Ieghmani Organics Limited	63.21	NA	NA	NA
Iss	ssuer	19.33%	NA	NA	NA
RoN Pe	eer Group:				
$W = \frac{1}{\text{At}}$	tul Limited	12.03%	NA	NA	NA
M	Ieghmani Organics Limited	15.11%	NA	NA	NA
NAV per share Iss	suer	13.32	NA	NA	NA
	eer Group:				
	tul Limited	1555.42	NA	NA	NA
M	Ieghmani Organics Limited	65.11	NA	NA	NA

14 Any other material information

- i. Ambey Laboratories Limited has informed the Exchange about the Appointment of Internal Auditor, Cost Auditor and Internal Auditor on 24-09-2024
- ii. Ambey Laboratories Limited has informed the Exchange regarding raising of fund by way of issuance of 310 Series B Unlisted, Secured, Redeemable Non-Convertible Debenture of face value of INR. 1,00,000/- each (Rs. One Lakh Only), aggregating to INR. 3,10,00,000 (Rs. Three Crores Ten Lac Only) on preferential basis by way of private placement to NP1 Capital Trust (acting through its trustee Orbis Trusteeship Services Private Limited) in one or more tranches and increase the borrowing Limits of the Company under Section 180(1)(c) of the Companies Act, 2013 in a Board Meeting held on 09-10-2024
- iii. Ambey Laboratories Limited has informed the Exchange regarding raising of fund by way of issuance of 310 Series B Unlisted, Secured, Redeemable Non-Convertible Debenture of face value of INR. 1,00,000/- each (Rs. One Lakh Only), aggregating to INR. 3,10,00,000 (Rs. Three Crores Ten Lac Only) on preferential basis by way of private placement to RevX Capital Fund I (acting through its Investment Manager revX Advisors LLP) in one or more tranches in a Board Meeting held on 22-10-2024 and all the resolutions passed in the meeting held on 09-10-2024 are null and void, and shall be treated as if they were never passed.

Note: For further updates and information, please refer stock exchange websites i.e. www.nseindia.com